Bridging With Low-Molecular-Weight Heparin Versus Antiplatelet Therapy in Patients Undergoing Noncardiac Surgery After Percutaneous Coronary Intervention: A Comprehensive Review

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-09-11 DOI:10.1002/clc.70008

Syed Javaid Iqbal, Zulfiqar Qutrio Baloch, Jahanzeb Malik, Nikeeta Bhimani, Amin Mehmoodi, Vishal Gupta

{"title":"Bridging With Low-Molecular-Weight Heparin Versus Antiplatelet Therapy in Patients Undergoing Noncardiac Surgery After Percutaneous Coronary Intervention: A Comprehensive Review","authors":"Syed Javaid Iqbal, Zulfiqar Qutrio Baloch, Jahanzeb Malik, Nikeeta Bhimani, Amin Mehmoodi, Vishal Gupta","doi":"10.1002/clc.70008","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>This review article discussed the use of bridging therapy with low-molecular-weight heparin (LMWH) in patients who undergo noncardiac surgery (NCS) after percutaneous coronary intervention (PCI).</p>\n </section>\n \n <section>\n \n <h3> Hypotheses</h3>\n \n <p>Patients who undergo PCI are at an increased risk of thrombotic events due to their underlying cardiovascular disease. However, many of these patients may require NCS at some point in their lives, which poses a significant challenge for clinicians as they balance the risk of thrombotic events against the risk of bleeding associated with antithrombotic therapy.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>This review evaluates the current evidence on the use of bridging therapy with LMWH in patients undergoing NCS after PCI, focusing on outcomes related to the efficacy and safety of antithrombotic therapy. The article also discusses the limitations of the current evidence and highlights areas where further research is needed to optimize the management of antithrombotic therapy in this patient population.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The goal of this review was to provide clinicians with a comprehensive summary of the available evidence to guide clinical decision-making and improve patient outcomes.</p>\n </section>\n </div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.70008","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.70008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

This review article discussed the use of bridging therapy with low-molecular-weight heparin (LMWH) in patients who undergo noncardiac surgery (NCS) after percutaneous coronary intervention (PCI).

Hypotheses

Patients who undergo PCI are at an increased risk of thrombotic events due to their underlying cardiovascular disease. However, many of these patients may require NCS at some point in their lives, which poses a significant challenge for clinicians as they balance the risk of thrombotic events against the risk of bleeding associated with antithrombotic therapy.

Results

This review evaluates the current evidence on the use of bridging therapy with LMWH in patients undergoing NCS after PCI, focusing on outcomes related to the efficacy and safety of antithrombotic therapy. The article also discusses the limitations of the current evidence and highlights areas where further research is needed to optimize the management of antithrombotic therapy in this patient population.

Conclusion

The goal of this review was to provide clinicians with a comprehensive summary of the available evidence to guide clinical decision-making and improve patient outcomes.

Abstract Image

查看原文本刊更多论文

经皮冠状动脉介入术后接受非心脏手术患者的低分子量肝素桥接疗法与抗血小板疗法：全面回顾

背景本文综述了经皮冠状动脉介入治疗（PCI）后接受非心脏手术（NCS）的患者使用低分子量肝素（LMWH）进行桥接治疗的情况。假设接受 PCI 的患者因其潜在的心血管疾病而增加了发生血栓事件的风险。然而，这些患者中的许多人可能在其生命的某个阶段需要接受 NCS，这给临床医生带来了巨大的挑战，因为他们需要平衡血栓事件的风险和抗血栓治疗相关的出血风险。结果本综述评估了PCI术后接受NCS的患者使用LMWH进行桥接治疗的现有证据，重点关注与抗血栓治疗的疗效和安全性相关的结果。文章还讨论了现有证据的局限性，并强调了需要进一步研究的领域，以优化此类患者的抗血栓治疗管理。结论本综述旨在为临床医生提供现有证据的全面总结，以指导临床决策并改善患者预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464